<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4298</id>
  <title>T3D4244</title>
  <common-name>Progesterone</common-name>
  <description>The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. Progesterone is a C-21 steroid hormone involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species. Progesterone belongs to a class of hormones called progestagens, and is the major naturally occurring human progestagen. During implantation and gestation, progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy. Progesterone decreases contractility of the uterine smooth muscle. The fetus metabolizes placental progesterone in the production of adrenal mineralo- and glucosteroids. A drop in progesterone levels is possibly one step that facilitates the onset of labor. In addition progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production.</description>
  <cas>57-83-0</cas>
  <pubchem-id>5994</pubchem-id>
  <chemical-formula>C21H30O2</chemical-formula>
  <weight>314.5</weight>
  <appearance>White powder.</appearance>
  <melting-point>121°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>8.81 mg/L (at 25°C)</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Progesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours.</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.</mechanism-of-toxicity>
  <metabolism>Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones.Route of Elimination: The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. Progesterone metabolites are excreted mainly by the kidneys.Half Life: 34.8-55.13 hours</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>2B, possibly carcinogenic to humans. (L135)</carcinogenicity>
  <use-source>For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Chronically high levels of progesterone are associated with at least 3 inborn errors of metabolism including: Congenital adrenal hyperplasia, Adrenal Hyperplasia Type 3 and Adrenal hyperplasia type 5.</health-effects>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:01:46Z</created-at>
  <updated-at type="dateTime">2026-04-17T17:48:11Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Progesterone</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00410</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>17026</chebi-id>
  <biocyc-id>CPD-272</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB00396</drugbank-id>
  <pdb-id>STR</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C</moldb-smiles>
  <moldb-formula>C21H30O2</moldb-formula>
  <moldb-inchi>InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1</moldb-inchi>
  <moldb-inchikey>RJKFOVLPORLFTN-LEKSSAKUSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">314.4617</moldb-average-mass>
  <moldb-mono-mass type="decimal">314.224580204</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>3.87</logp>
  <hmdb-id>HMDB01830</hmdb-id>
  <chembl-id>CHEMBL103</chembl-id>
  <chemspider-id>5773</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Nejib M. Nasraoui, Alain Piasco, &amp;#8220;Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them.&amp;#8221; U.S. Patent US5223492, issued May, 1971.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003204</chemdb-id>
  <dsstox-id>DTXSID3022370</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00010899</susdat-id>
  <iupac>(1S,2R,10S,11S,14S,15S)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one</iupac>
</compound>
